Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA recommends approval for Novartis’ CTL019 to treat r/r B-cell ALL

pharmaceutical-technologyJuly 17, 2017

Tag: FDA , Novartis

PharmaSources Customer Service